AR088563A1 - Derivado de n-tienilbenzamida sustituido con aminoalquilo - Google Patents

Derivado de n-tienilbenzamida sustituido con aminoalquilo

Info

Publication number
AR088563A1
AR088563A1 ARP120104035A ARP120104035A AR088563A1 AR 088563 A1 AR088563 A1 AR 088563A1 AR P120104035 A ARP120104035 A AR P120104035A AR P120104035 A ARP120104035 A AR P120104035A AR 088563 A1 AR088563 A1 AR 088563A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
alkylene
lower alkylene
alkyl
substituted
Prior art date
Application number
ARP120104035A
Other languages
English (en)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR088563A1 publication Critical patent/AR088563A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Abstract

Un compuesto que tiene una actividad inhibidora del transportador intestinal de fosfato (NPT-IIb) y resulta de utilidad como ingrediente activo de un agente para tratar y/o prevenir la hiperfosfatemia. Compuesto que tiene actividad inhibidora del NPT-IIb y que resulta de utilidad como ingrediente activo de un agente para tratar y/o prevenir la hiperfosfatemia. Como resultado, crearon un derivado de N-tienilbenzamida sustituido con aminoalquilo que tiene acción inhibidora de NPT-IIb, y de ese modo concretaron la presente. El derivado de N-tienilbenzamida sustituido con aminoalquilo la presente tiene una actividad inhibidora de NPT-IIb y se puede usar como agente para prevenir o tratar la hiperfosfatemia. Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales, donde X¹ representa CH₂ u O; k representa 1, 2 ó 3; R³ representa H o alquilo inferior; X² representa CH o N; L¹ representa alquileno inferior; R¹ representa H o alquilo inferior; X³ representa CH o N; L² representa alquileno inferior; R⁵ representa H o alquilo inferior; R⁶ representa H, alquilo inferior, alquilo inferior sustituido con uno a dos de -OR⁰, -C(O)-alquilo inferior, -S(O)ₘ-alquilo inferior, -alquileno inferior-N(alquilo inferior)₂, -R⁰⁰-heterociclo, -R⁰⁰-fenilo, o -R⁰⁰-cicloalquilo, donde el heterociclo, fenilo y cicloalquilo puede estar sustituido con uno a dos alquilo inferior o C(O)-alquilo inferior, y -R⁰⁰ puede estar sustituido con un -OR⁰; R⁰⁰ representa una unión o alquileno inferior; R⁰ representa H o alquilo inferior; m representa 0, 1 ó 2; L³ representa alquileno inferior; n representa 0 ó 1; R⁴ representa H, alquilo inferior, -alquileno inferior-COO-R⁰, -alquileno inferior-OR⁰, -alquileno inferior-NHR⁰, -alquileno inferior-N(alquilo inferior)₂, o cicloalquilo; L⁴ representa una unión, O ó -NR⁰-; Y representa -R⁰⁰-heterociclo monocíclico-R⁰⁰-, -R⁰⁰-fenilo-R⁰⁰-, -alquileno inferior-NR⁰-alquileno inferior-, alquileno inferior-O-alquileno inferior- o alquileno inferior, los cuales pueden estar sustituidos con un grupo hidroxilo; y R² representa H o alquilo inferior.
ARP120104035A 2011-10-27 2012-10-26 Derivado de n-tienilbenzamida sustituido con aminoalquilo AR088563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011236533 2011-10-27

Publications (1)

Publication Number Publication Date
AR088563A1 true AR088563A1 (es) 2014-06-18

Family

ID=48167891

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104035A AR088563A1 (es) 2011-10-27 2012-10-26 Derivado de n-tienilbenzamida sustituido con aminoalquilo

Country Status (16)

Country Link
US (1) US9062032B2 (es)
EP (1) EP2772490B1 (es)
JP (2) JP6020460B2 (es)
KR (1) KR101941048B1 (es)
CN (1) CN103906741B (es)
AR (1) AR088563A1 (es)
AU (1) AU2012329913A1 (es)
CA (1) CA2853688C (es)
EA (1) EA023955B1 (es)
ES (1) ES2585415T3 (es)
IL (1) IL232230A0 (es)
IN (1) IN2014CN03130A (es)
MX (1) MX342521B (es)
PL (1) PL2772490T3 (es)
TW (1) TW201323419A (es)
WO (1) WO2013062065A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20150043A2 (ro) 2012-10-02 2015-08-31 Epitherapeutics Aps Inhibitori ai histon-demetilazelor
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
PL2975030T3 (pl) 2013-03-13 2021-01-11 Chugai Seiyaku Kabushiki Kaisha Pochodna dihydropirydazyno-3,5-dionu
TWI594975B (zh) * 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
WO2015153498A1 (en) * 2014-03-31 2015-10-08 Epitherapeutics, Aps Inhibitors of histone demethylases
CN105658635B (zh) * 2014-08-22 2019-03-08 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用
EP3192511B1 (en) 2014-09-12 2021-07-14 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
CA2962724C (en) 2014-09-26 2019-11-19 Daiichi Sankyo Company, Limited Salt of dicarboxylic acid compound
CN105524053B (zh) * 2014-10-19 2020-06-05 广东东阳光药业有限公司 四氢苯并噻吩化合物
TW201700458A (zh) 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
CN107082773B (zh) * 2016-02-16 2020-07-28 江苏恒瑞医药股份有限公司 一种肠2b型磷酸钠协同转运蛋白抑制剂的硫酸盐及其结晶形式
JP6653410B2 (ja) * 2016-08-15 2020-02-26 イーライ リリー アンド カンパニー ＮａＰｉ−ＩＩｂ阻害剤として有用な縮合チオフェン誘導体
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
CN109422723B (zh) * 2017-08-25 2021-02-23 江苏恒瑞医药股份有限公司 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
IL309056A (en) 2021-06-08 2024-02-01 Chugai Pharmaceutical Co Ltd A preparation containing a DIHYDROPYRIDAZINE-3,5-DIONE derivative
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2023203254A2 (en) 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028353A2 (en) * 2000-10-05 2002-04-11 Smithkline Beecham Corporation Phosphate transport inhibitors
JP2007131532A (ja) 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
AU2002354410A1 (en) 2001-12-05 2003-06-17 Japan Tobacco Inc. Triazole compound and medicinal use thereof
US8134015B2 (en) 2003-03-27 2012-03-13 Kyowa Hakko Kirin Co., Ltd. Compound inhibiting in vivo phosphorous transport and medicine containing the same
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
AU2005279845A1 (en) 2004-08-30 2006-03-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using RNase H inhibitors
EP1802634A2 (en) 2004-10-20 2007-07-04 Compass Pharmaceuticals LLC Thiophens and their use as anti-tumor agents
NZ586094A (en) * 2008-01-08 2012-06-29 Purdue Pharma Lp Proline analogs as ligands for cannabinoid receptors for the treatment of pain
EP2565190B1 (en) 2010-04-28 2015-06-03 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012006473A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Also Published As

Publication number Publication date
PL2772490T3 (pl) 2016-11-30
CA2853688C (en) 2018-06-12
CA2853688A1 (en) 2013-05-02
ES2585415T3 (es) 2016-10-05
BR112014010169A2 (pt) 2017-04-25
KR101941048B1 (ko) 2019-01-22
IN2014CN03130A (es) 2015-07-03
MX342521B (es) 2016-10-03
JP2013107880A (ja) 2013-06-06
EP2772490A4 (en) 2015-01-21
EP2772490A1 (en) 2014-09-03
US9062032B2 (en) 2015-06-23
MX2014005090A (es) 2015-02-12
EA201490875A1 (ru) 2014-09-30
EA023955B1 (ru) 2016-07-29
EP2772490B1 (en) 2016-04-06
KR20140096322A (ko) 2014-08-05
JP6020460B2 (ja) 2016-11-02
CN103906741A (zh) 2014-07-02
JPWO2013062065A1 (ja) 2015-04-02
AU2012329913A1 (en) 2014-05-22
CN103906741B (zh) 2016-01-20
WO2013062065A1 (ja) 2013-05-02
US20150031727A1 (en) 2015-01-29
IL232230A0 (en) 2014-06-30
TW201323419A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
AR088563A1 (es) Derivado de n-tienilbenzamida sustituido con aminoalquilo
AR092211A1 (es) Derivados de hidropirrolopirrol
AR098908A1 (es) Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo-8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4]triazina-1-carboxamida
UY35243A (es) Inhibidores de fosfatidilinositol 3-cinasa
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR095326A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
AR087995A1 (es) Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida
AR100191A1 (es) Método para tratar adenocarcinoma de pulmón
AR094313A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR089527A1 (es) Inhibidores de bromodominios
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
BR112017000242A2 (pt) composto, cristal, inibidor de axl, medicamento, composição farmacêutica, métodos para tratamento de uma doença, para prevenção de metástases de câncer, para superar a resistência a drogas de um câncer e para inibir a aquisição de resistência a drogas de um câncer, e, uso de um composto
AR085195A1 (es) Metodo de tratamiento de cancer
AR097086A1 (es) Derivados 1,3-disustituidos de ciclopentano
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
AR080703A1 (es) Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
AR098522A1 (es) Compuesto de triazolo-piridina
CR20140380A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina
AR091586A1 (es) Derivado de amida o su sal como inhibidor de la produccion de colageno
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
AR089623A1 (es) Inhibidores de iap
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
ITMI20120909A1 (it) Dispositivo di pulitura

Legal Events

Date Code Title Description
FB Suspension of granting procedure